TNFRSF1A and early-onset autosomal dominant Alzheimer disease: In the present study, baseline levels of CSF TNF-α, TNFR-1, and TNFR-2 were explored, and the potential to be used as a biomarker was assessed to differentiate between individuals who remain stable compared to those who experience disease progression over 10 years in the Alzheimer’s Disease Neuroimaging Initiative (ADNI).